GeneSegues, Inc. Appoints New SAB Member

Published: Dec 10, 2003

GeneSegues, Inc., a biopharmaceutical company that develops nanoencapsulated therapeutics, today announced the appointment of Dr. Erkki Ruoslahti, Ph.D., M.D., to its Scientific Advisory Board (SAB). Dr. Ruoslahti holds the position of Distinguished Professor at the Burnham Institute in La Jolla, California.

Back to news